Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
CellectisS. A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.
It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
The company was founded in 1999 and is headquartered in Paris, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 25 | 0.00 Increased by +100.00% | -0.20 Increased by +100.00% |
| May 13, 25 | -0.17 Increased by +75.71% | -0.24 Increased by +29.17% |
| Mar 14, 25 | -0.16 Increased by +77.14% | -0.09 Decreased by -77.78% |
| Nov 4, 24 | -0.23 Increased by +25.81% | -0.21 Decreased by -9.52% |
| Aug 6, 24 | -0.28 Decreased by -47.37% | -0.30 Increased by +6.67% |
| Apr 29, 24 | -0.70 Decreased by -20.69% | -0.22 Decreased by -218.18% |
| Mar 13, 24 | -0.70 Decreased by -18.64% | -0.22 Decreased by -218.18% |
| Nov 6, 23 | -0.31 Increased by +50.79% | -0.42 Increased by +26.19% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 10.65 M Increased by +135.31% | -18.13 M Decreased by -421.25% | Decreased by -170.14% Decreased by -236.52% |
| Dec 31, 24 | 12.72 M Increased by +4.39 K% | 5.92 M Increased by +113.82% | Increased by +46.57% Increased by +100.31% |
| Sep 30, 24 | 16.20 M Increased by +10.35 K% | -23.06 M Decreased by -31.88% | Decreased by -142.32% Increased by +98.74% |
| Jun 30, 24 | 8.06 M Increased by +4.43 K% | -25.27 M Decreased by -137.32% | Decreased by -313.48% Increased by +94.76% |
| Mar 31, 24 | 4.53 M Increased by +3.16 K% | 5.64 M Increased by +118.76% | Increased by +124.62% Increased by +100.58% |
| Dec 31, 23 | 283.00 K Decreased by -98.23% | -42.86 M Decreased by -66.77% | Decreased by -15.15 K% Decreased by -9.34 K% |
| Sep 30, 23 | 155.00 K Decreased by -28.57% | -17.48 M Increased by +29.15% | Decreased by -11.28 K% Increased by +0.81% |
| Jun 30, 23 | 178.00 K Decreased by -86.80% | -10.65 M Increased by +43.80% | Decreased by -5.98 K% Decreased by -325.60% |